141 related articles for article (PubMed ID: 17257714)
1. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
Dorrell L; Williams P; Suttill A; Brown D; Roberts J; Conlon C; Hanke T; McMichael A
Vaccine; 2007 Apr; 25(17):3277-83. PubMed ID: 17257714
[TBL] [Abstract][Full Text] [Related]
2. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
[TBL] [Abstract][Full Text] [Related]
3. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
Ondondo BO; Yang H; Dong T; di Gleria K; Suttill A; Conlon C; Brown D; Williams P; Rowland-Jones SL; Hanke T; McMichael AJ; Dorrell L
Eur J Immunol; 2006 Oct; 36(10):2585-94. PubMed ID: 17013989
[TBL] [Abstract][Full Text] [Related]
4. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
Mwau M; Cebere I; Sutton J; Chikoti P; Winstone N; Wee EG; Beattie T; Chen YH; Dorrell L; McShane H; Schmidt C; Brooks M; Patel S; Roberts J; Conlon C; Rowland-Jones SL; Bwayo JJ; McMichael AJ; Hanke T
J Gen Virol; 2004 Apr; 85(Pt 4):911-919. PubMed ID: 15039533
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
Cebere I; Dorrell L; McShane H; Simmons A; McCormack S; Schmidt C; Smith C; Brooks M; Roberts JE; Darwin SC; Fast PE; Conlon C; Rowland-Jones S; McMichael AJ; Hanke T
Vaccine; 2006 Jan; 24(4):417-25. PubMed ID: 16176847
[TBL] [Abstract][Full Text] [Related]
6. Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.
Yang H; Dong T; Turnbull E; Ranasinghe S; Ondondo B; Goonetilleke N; Winstone N; di Gleria K; Bowness P; Conlon C; Borrow P; Hanke T; McMichael A; Dorrell L
J Immunol; 2007 Jul; 179(1):597-606. PubMed ID: 17579081
[TBL] [Abstract][Full Text] [Related]
7. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
Dorrell L; Yang H; Ondondo B; Dong T; di Gleria K; Suttill A; Conlon C; Brown D; Williams P; Bowness P; Goonetilleke N; Rostron T; Rowland-Jones S; Hanke T; McMichael A
J Virol; 2006 May; 80(10):4705-16. PubMed ID: 16641264
[TBL] [Abstract][Full Text] [Related]
8. Development of a DNA-MVA/HIVA vaccine for Kenya.
Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
[TBL] [Abstract][Full Text] [Related]
10. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
Wee EG; Patel S; McMichael AJ; Hanke T
J Gen Virol; 2002 Jan; 83(Pt 1):75-80. PubMed ID: 11752703
[TBL] [Abstract][Full Text] [Related]
11. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
[TBL] [Abstract][Full Text] [Related]
12. Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses.
Climent N; Munier S; Piqué N; García F; Pavot V; Primard C; Casanova V; Gatell JM; Verrier B; Gallart T
Vaccine; 2014 Oct; 32(47):6266-76. PubMed ID: 25240755
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
Jaoko W; Nakwagala FN; Anzala O; Manyonyi GO; Birungi J; Nanvubya A; Bashir F; Bhatt K; Ogutu H; Wakasiaka S; Matu L; Waruingi W; Odada J; Oyaro M; Indangasi J; Ndinya-Achola J; Konde C; Mugisha E; Fast P; Schmidt C; Gilmour J; Tarragona T; Smith C; Barin B; Dally L; Johnson B; Muluubya A; Nielsen L; Hayes P; Boaz M; Hughes P; Hanke T; McMichael A; Bwayo J; Kaleebu P
Vaccine; 2008 May; 26(22):2788-95. PubMed ID: 18440674
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
Rosario M; Fulkerson J; Soneji S; Parker J; Im EJ; Borthwick N; Bridgeman A; Bourne C; Joseph J; Sadoff JC; Hanke T
J Virol; 2010 Aug; 84(15):7815-21. PubMed ID: 20484495
[TBL] [Abstract][Full Text] [Related]
15. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
Peters BS; Jaoko W; Vardas E; Panayotakopoulos G; Fast P; Schmidt C; Gilmour J; Bogoshi M; Omosa-Manyonyi G; Dally L; Klavinskis L; Farah B; Tarragona T; Bart PA; Robinson A; Pieterse C; Stevens W; Thomas R; Barin B; McMichael AJ; McIntyre JA; Pantaleo G; Hanke T; Bwayo J
Vaccine; 2007 Mar; 25(11):2120-7. PubMed ID: 17250931
[TBL] [Abstract][Full Text] [Related]
16. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.
Thompson M; Heath SL; Sweeton B; Williams K; Cunningham P; Keele BF; Sen S; Palmer BE; Chomont N; Xu Y; Basu R; Hellerstein MS; Kwa S; Robinson HL
PLoS One; 2016; 11(10):e0163164. PubMed ID: 27711228
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
Howles S; Guimarães-Walker A; Yang H; Hancock G; di Gleria K; Tarragona-Fiol T; Hayes P; Gilmour J; Bridgeman A; Hanke T; McMichael A; Dorrell L
Vaccine; 2010 Oct; 28(45):7306-12. PubMed ID: 20816902
[TBL] [Abstract][Full Text] [Related]
18. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
[TBL] [Abstract][Full Text] [Related]
19. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
[TBL] [Abstract][Full Text] [Related]
20. Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.
Slyker JA; Lohman BL; Mbori-Ngacha DA; Reilly M; Wee EG; Dong T; McMichael AJ; Rowland-Jones SL; Hanke T; John-Stewart G
Vaccine; 2005 Sep; 23(38):4711-9. PubMed ID: 16043269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
